Are paper drinking straws better than plastic ones? The answer may surprise you
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Human Osteoblasts Market to Reach US$ 87.1 Million by 2033
The market is currently experiencing robust growth, fueled by a post-pandemic surge in orthopedic surgeries and significant investment in regenerative medicine. Innovations in 3D bioprinting and smart scaffolds are creating new therapeutic possibilities for bone repair. Chicago, Aug. 20, 2025 (GLOBE NEWSWIRE) -- The global human osteoblasts market was valued at US$ 48.2 million in 2024 and is expected to reach US$ 87.1 million by 2033 at a CAGR of 6.8% during the forecast period 2025–2033. The future potential of the human osteoblasts market lies in the convergence of artificial intelligence with advanced biomanufacturing. AI-powered platforms are now capable of analyzing genomic data from 1000s of individuals to predict osteoblast response to new drug compounds, drastically reducing discovery timelines. This synergy is enabling the creation of patient-specific 3D-bioprinted bone grafts. As of 2025, researchers are successfully embedding patient-derived osteoblasts into custom scaffolds with 95% cell viability post-printing. These constructs are being tested in preclinical models for craniofacial reconstruction and spinal fusion, promising a new era of personalized regenerative medicine. Demand for highly characterized osteoblasts for these applications is projected to soar. Download Sample Pages: Another significant growth frontier of the human osteoblasts market is the application of osteoblast research to counteract microgravity-induced bone loss in astronauts. With 3 new long-duration space missions planned by international agencies before 2028, research into osteoblast function in simulated microgravity is intensifying. Furthermore, the veterinary orthopedics market represents a substantial, untapped opportunity. In 2024, an estimated 1.2 million companion animals in the U.S. alone underwent procedures for fractures or degenerative joint diseases. The development of canine and equine osteoblast cell lines for testing new veterinary implants and cell-based therapies is an emerging field that could create an entirely new vertical within the broader market. Key Findings in Human Osteoblasts Market Market Forecast (2033) US$ 87.1 million CAGR 6.8% Top Drivers Rising prevalence of osteoporosis and degenerative bone diseases globally. Technological advancements in cell-based therapies and tissue engineering. Increasing geriatric population driving demand for orthopedic surgical procedures. Top Trends Shift towards personalized medicine using patient-derived osteoblast cultures. Development of 3D bioprinting for creating patient-specific bone grafts. Growing adoption of minimally invasive bone regeneration surgical techniques. Top Challenges Expensive cell-based therapies and procedures. Stringent and complex regulatory approval pathways for new biologics. Top 12 Key Players Strategically Dominate the Evolving Global Human Osteoblasts Market The competitive environment is both concentrated and highly specialized. Analysis in 2024 consistently identifies 12 key players shaping the industry. These include Sigma-Aldrich, Athersys Inc., Cerapedics Inc., CryoLife, Inc., and Cytori Therapeutics Inc. Other notable companies are USA Stem Cell Inc., Vericel Corporation, Wright Medical Group N.V, Biocomposites, BD, Zimmer Biomet, and PromoCell. In the crucial U.S. orthopedic biomaterials sector, a key application area, 3 major competitors—Medtronic, DePuy Synthes, and Stryker—were noted as dominant forces in 2024. Suppliers offer highly specific product lines to meet diverse research needs. As of 2025, PromoCell provides 4 primary product categories related to osteoblasts, including cells and specialized growth media. Similarly, Innoprot offers 2 distinct types of primary human osteoblasts as of 2024 Human Calvarial and Human Femoral Osteoblasts in the human osteoblasts market. InSCREENex provides 1 specific immortalized human osteoblast cell line, CI-huOB. Product quality and performance are paramount. Lonza guarantees 10 population doublings for its Clonetics™ Normal Human Osteoblasts, ensuring robust expansion for 2024 research. Innoprot's immortalized cells demonstrate a growth potential of over 30+ passages, a significant advantage. Recent Product and Technology Launches Signal Rapid Advancement Within the Market Innovation remains a cornerstone of human osteoblasts market growth, with companies actively launching advanced products. On April 15, 2024, CryoLife, Inc. introduced 1 new osteoblast culture system designed to enhance cell viability. Zimmer Biomet followed suit in February 2024, launching 1 new bioreactor system for osteoblast cultivation with improved scalability. Innovation extends to cell preservation. In 2024, PromoCell released 1 new protein- and animal component-free cryopreservation medium, Cryo-SFM Plus, featuring advanced antioxidant technology. Intellectual property is also a key competitive tool. Bone Solutions Inc. was awarded 5 new patents in fiscal year 2025 for its Mg OSTEOCRETE technology, a bone substitute that stimulates osteoblast activity. Practical usability is crucial for clinical adoption. Bone Solutions' Mg OSTEOCRETE boasts a preparation time of just 30 seconds, a significant handling benefit for 2025 applications. To support adjacent research fields, PromoCell also launched 1 new Cancer Media Toolbox in 2024 to facilitate the establishment of primary cancer cell lines and complex 3D tumor models. Active Clinical Trials for Osteoblast-Related Therapies Underpin Future Market Expansion The clinical development pipeline is a strong indicator of future commercial opportunities. In February 2024, Biocomposites initiated 2 Phase 2 clinical trials for its STIMULAN VG® bone graft substitute. These trials will assess efficacy in treating diabetic foot osteomyelitis and stage 4 pressure ulcers. Osteosarcoma research, a critical area for the human osteoblasts market, is also advancing. In 2024, the Osteosarcoma Institute (OSI) sponsored 1 Phase 2 clinical trial in Spain for OMO-103, a promising MYC inhibitor. A remarkable 25 months was the fast-tracked timeline to launch the OMO-103 trial, showcasing increased efficiency in clinical development. In the United States, a 2024 study was published on 1 FDA/IRB-approved GMP-manufactured stem cell product, PSC-01, for knee osteoarthritis. The study showed that a single treatment provided pain reduction and increased function for 2.5 years. Research methodologies are also being refined. A 2024 clinical trial enrolled 30 patients to analyze the effects of lasers on alveolar bone preservation. A Phase 1 trial protocol published in 2024 detailed a 3+3 dose escalation method for a study using human umbilical cord-derived osteoblasts for femoral head osteonecrosis. Favorable Regulatory Approvals in 2024 Create a Promising Outlook for Therapies The regulatory climate for cell and gene therapies in the human osteoblasts market became increasingly favorable in 2024. The FDA approved 7 new cell and gene therapy products Amtagvi, Aucatzyl, Beqvez, Kebilidi, Ryoncil, Symvess, and Tecelra. The pace of approvals is accelerating, with 3 of these therapies gaining approval in early 2024 alone. On December 19, 2024, the FDA approved 1 mesenchymal stem cell product, Ryoncil from Mesoblast. Another landmark approval was granted on November 13, 2024, for 1 gene therapy for AADC deficiency, Kebilidi from PTC Therapeutics. On November 8, 2024, the FDA approved 1 CD19-directed T-cell immunotherapy, obecabtagene autoleucel (Aucatzyl), from Autolus Inc. The recommended dose for Aucatzyl is 410x10^6 CAR-positive viable T-cells. StemCyte received approval for 1 allogeneic hematopoietic stem cell therapy, Regenecyte, on November 26, 2024. Patent activity, a precursor to commercialization, is also strong. Innovators at the University of Pittsburgh were issued 5 patents in August 2024, while University of Minnesota researchers secured 111 US patents in 2024 for various health science discoveries. Significant Funding and Strategic Grants Accelerate Osteoblast-Focused Research and Development Robust financial investment is fueling the engine of scientific discovery across the global human osteoblasts market. The Osteosarcoma Institute (OSI) awarded $1,100,000 to 3 groundbreaking osteosarcoma research projects during its 2023–2024 grant cycle. One of these grants provided $500,000 in funding to Dr. David Lyden's team for a project focused on metastasis. The impact of such funding is often magnified. Building on an initial OSI grant, Baylor College of Medicine secured $4,500,000 in additional funding in 2024 to advance CAR-T therapy research. International collaborations are also being funded. In October 2024, one US–Israel Binational Science Foundation grant was awarded to a team including University of Vermont Cancer Center members to study osteosarcoma epigenetics. Wherein, government funding remains critical. In August 2024, Medical College of Georgia scientists received a five-year grant of $2,400,000 from the National Institute on Aging to study how stress hormones signal the skeleton. Philanthropic efforts are also significant, with over $4,600,000 raised from more than 1,000 donations in 2024 to support the OSI's vital mission. Diverse and Critical Applications Are Driving Widespread Adoption Across Multiple Fields The utility of human osteoblasts market extends across a wide spectrum of research and clinical applications. The dynamic interplay between 2 key cell types, osteoblasts and osteoclasts, is central to bone health, driving research into osteoporosis. In the laboratory, standardized protocols are essential. Human osteoblasts from PromoCell require approximately 3 weeks to show detectable mineralization in culture. Advanced 3D modeling is becoming a standard research tool. InSCREENex's immortalized human osteoblasts can form 3D "mini-bones" when cultured under specific conditions. Suppliers like PromoCell target 3 key application areas cell expansion, culture initiation, and differentiation. A 2024 study highlighted the use of 1 new 3D model based on human fetal osteoblasts to study osteocyte commitment. The clinical relevance is clear. The classic period for new bone formation after a tooth extraction, a process driven by osteoblasts, is 6-10 weeks. A 2025 study analyzed ion release from 3D printed scaffolds at 3 days, 7 days, and 15 days, key time points for osteoblast interaction. Quality Guarantees and Emerging Technologies Redefine the Global Human Osteoblasts Market The reliability of research outcomes depends on the quality of the underlying cell products. Suppliers in the market provide stringent quality guarantees. PromoCell guarantees >500,000 viable cells per cryovial after thawing. Innoprot similarly ensures >500,000 viable cells in each vial, cryopreserved at passage one, while Lonza guarantees ≥500,000 viable cells per ampule. For immortalized lines, Innoprot provides >1,000,000 viable cells per vial, and InSCREENex includes >0.5 million viable cells per vial. Longevity in culture is also specified. Innoprot guarantees 15 population doublings for its primary osteoblasts post-delivery. PromoCell recommends a split ratio of 1:3 to 1:6 for its primary cells. To support targeted research, PromoCell holds >100 HLA-typed cell donors in stock as of 2024, offering 4-digit high-resolution typing. The InSCREENex cell line was derived from a 63-year-old female donor. Concurrently, emerging technologies are creating new opportunities for the human osteoblasts market. Three key trends noted in the 2024 orthopedic biomaterials market are biodegradable materials, 3D printing, and nanotechnology. A September 2024 paper detailed 1 study using collagen-based 3D printed scaffolds to investigate osteoblast activity. A May 2024 publication described 1 new 3D in-vitro model using human fetal osteoblasts. A 2025 study utilized 2 cell lines to test 3D printed composite samples, using standards prepared from 1,000 mg/L stock solutions and a plating density of 10,000 cells/well for viability tests. Customize the Data Scope to Match Your Objectives: Strategic Alliances and Focused Regional Developments Indicate Strong Global Market Growth Corporate strategies and regional activities in 2024 and 2025 underscore a commitment to global expansion of the human osteoblasts market. On March 10, 2024, 1 major collaboration was announced between Athersys Inc. and Cerapedics Inc. to develop a novel osteoblast-based therapy. Service providers are also expanding. In 2024, Thermo Fisher launched its "Accelerator™ Drug Development" solutions, offering 360-degree support to biotech companies. Licensing agreements are expanding market access for key biologics. Bio-Thera Solutions entered into 1 exclusive licensing agreement on December 24, 2024, for its ustekinumab biosimilar. On the same day, GlycoNex announced 1 licensing agreement for its denosumab biosimilar, a therapy for bone loss. Regional market activities are intensifying. In 2024, 1 pivotal Phase 2 trial for osteosarcoma was opened in Barcelona, Spain. Stryker expanded with 1 new testing facility in India in February 2024. In May 2024, Sanofi announced 1 new partnership with OpenAI to accelerate R&D. The North American market saw the FDA grant 1 US approval to Pfizer's Beqvez on April 25, 2024. Europe showed activity with 1 approval by the UK's MHRA on January 15, 2025. The Asia-Pacific region is also growing, evidenced by 1 approval in Japan on January 7, 2025, for Biocon's ustekinumab. Global Human Osteoblasts Market Major Players: Athelas Bionova Scientific Cell Signaling Technology Corning EMD Millipore Invitrogen Lonza Merck Group NantKwest Promega R and D Systems ReproCELL Sigma-Aldrich Stemcell Technologies Thermo Fisher Scientific Other Prominent Players Key Market Segmentation: By Product Human Cell Culture Osteoblast Cell Lines By Application Traumatic Injuries Road Accidents Regeneration Surgeries Orthopedics Musculoskeletal and Spine Neurology By End user Hospitals Specialty Clinics Ambulatory Surgical Centers By Region North America Europe Asia Pacific Middle East & Africa South America Need a Detailed Walkthrough of the Report? Request a Live Session: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
an hour ago
- Fast Company
What you can do about the government data that's disappearing
People rely on data from federal agencies every day – often without realizing it. Rural residents use groundwater level data from the U.S. geological survey's National Water Information System to decide where to dig wells. High school coaches turn to weather apps supported by data from the National Weather Service to decide when to move practice inside to avoid life-threatening heat. Emergency managers use data from the Census Bureau's American Community Survey to ensure that residents without vehicles have seats on evacuation buses during local emergencies. On Jan. 31, 2025, websites and datasets from across the federal government began to disappear. As that happened, archivists and researchers from around the world sprang into action, grabbing what they could before it was gone. Trust in the federal statistical system took another hit when Bureau of Labor Statistics Commissioner Erika McEntarfer was fired on the heels of a dismal Aug. 1, 2025, employment report. And reduced data collection at the bureau was already causing concern before her dismissal. The bureau has ceased collection of critical inputs to the Consumer Price Index, likely reducing that inflation indicator's accuracy, especially at the level of specific locations and products. As researchers of economics and epidemiology at the University of Michigan, we have spent years working with data, often from the federal government. When data and information began to disappear, we were spurred into action to preserve these important public goods. The Inter-university Consortium for Political and Social Research, where we work – commonly known as ICPSR – has been making data from governments and researchers available for more than 60 years. We are stewards of this data, preserving it and ensuring that it is accessible in a safe and responsible manner. Unfortunately, government data is now at risk of becoming less available or disappearing. But there are steps that researchers – and the public – can take to reduce that risk. Data at risk Some 8,000 pages were removed from federal websites within a few days of Jan. 31, 2025. Though many were soon restored following substantial outcry and some court orders, it's still unclear how the restored webpages and datasets may have been changed. In one preliminary examination, researchers found that 49% of the 232 datasets they reviewed had been substantially altered, including the replacement of the word 'gender' with 'sex.' This alteration can obscure nonbinary gender identities. Only 13% of the changes the researchers found were documented by the government. U.S. government data has also become less accessible because of mass firings of federal workers and the dismantling of entire agencies. Important efforts like the Data Rescue Project and the Internet Archive have been able to preserve a great deal of knowledge and data, but they are mostly limited to publicly available data and information. No one left to vet data Many important government data resources contain sensitive or identifying information. This means officials must vet requests before they grant access to data rescue efforts. But many agencies have had their ability to conduct vetting and manage access severely curtailed and, in some cases, eliminated altogether. Take the Pregnancy Risk Assessment Monitoring System, which provides key data on maternal and child health from around the United States. The Centers for Disease Control and Prevention integrates data collected at state and local levels and adds population information to come up with estimates. While some of this data is publicly available, access to most data from 2016 and later requires a request to the CDC and a signed data use agreement. At the start of 2025, multiple researchers reported to our team at the Inter-university Consortium for Political and Social Research that the CDC had stopped processing these requests. In February, researchers discovered that the Pregnancy Risk Assessment Monitoring System would be discontinued. The CDC suggested that data collection would restart at some point. But on April 1, the entire Pregnancy Risk Assessment Monitoring System team was laid off. This made one of the most valuable sources of data on the health of mothers and babies largely inaccessible, and put plans for its future in limbo. Similar situations have played out at other agencies, including the dismantled U.S. Agency for International Development and the National Center for Education Statistics. Data collected, cleaned and harmonized using taxpayer dollars is now languishing on inaccessible servers. Inaccessible data The portal that researchers use to apply for access to restricted federal statistical data now includes a list of data that researchers can no longer access. Some organizations are leading efforts to restore access to particular datasets. The Inter-university Consortium for Political and Social Research, for instance, has an agreement with USAID to preserve and provide access to USAID's education data. Unfortunately, these efforts barely scratch the surface. With very few staff left, there isn't a clear estimate of which other USAID resources remain inaccessible. According to our count, 354 restricted datasets from the federal statistical system's Standard Application Portal have become unavailable due to firings, layoffs and funding cuts. Data is critical for people and the state and local governments that represent them to make good decisions. Federal data is also used for oversight, so that researchers can verify that the government is doing what it's supposed to in accordance with its congressionally mandated missions. Government efficiency requires accountability. And accountability requires high-quality and timely data on operations. The mass firings of federal employees means that those tasked with ensuring this accountability are doing so while struggling to obtain necessary data. So where do we go from here? While the pace of intentional government data removal appears to have slowed, it hasn't stopped. New datasets under threat of disappearing are being rescued daily. Restructured federal agencies and related changes to – or neglect of – official websites can make data difficult or impossible to find. What you can do If you identify data that is at risk, perhaps because its collection has been discontinued or it covers a controversial topic, you can report your observations to the Data Rescue Project, a grassroots effort of archivists, librarians and other concerned people. The Data Rescue Project has been working for months to identify data and preserve government data, including in the Inter-university Consortium for Political and Social Research's DataLumos open-access archive. Similarly, the Public Environmental Data Partners, a coalition of nonprofits, archivists and researchers, are preserving federal environmental data and have a nomination form. Efforts to identify restored data that has been altered are also gaining steam. Dataindex tracks Federal Register notices that describe proposed changes to 24 widely used datasets from across the federal government, including the American Community Survey from the Census Bureau, the National Crime Victimization Survey from the Bureau of Justice Statistics, and the National Health Interview Survey from the CDC. The website also facilitates comment on proposed alterations. You can help researchers understand the scale of data alterations that have been, and continue to be, made. If you notice changes in public datasets, you can share that information with the American Statistical Association's FedStatMonitoring project. The Inter-university Consortium for Political and Social Research is continuing our efforts to ensure the preservation of, and access to, existing data, including from the Bureau of Labor Statistics and the Consumer Financial Protection Bureau. At the same time, we and other groups are planning future efforts in data collection to avoid gaps in our knowledge. The federal statistical system is both large and complex, including hundreds of thousands of datasets that people depend on in many ways, from weather forecasts to local economic indicators. If the federal government continues to step back from its role as a provider of high-quality, trusted data, others – including state and local governments, academia, nonprofits and companies – may need to fill the gap by stepping up to collect it.
Forbes
an hour ago
- Forbes
Valley Fever Cases Surge To Record Levels In California
California is experiencing an unprecedented surge in Valley Fever cases, with health officials warning that 2025 could shatter previous records. As of the end of July, there were 6,761 confirmed cases, which means if this pace continues, the total 2025 numbers will likely exceed the 12,595 cases reported in 2024. This dramatic increase has prompted renewed public health warnings and highlights the urgent need for greater awareness of this potentially serious fungal infection. What Causes Valley Fever and How Is It Transmitted? Coccidioidomycosis, commonly known as Valley Fever, is caused by the fungus Coccidioides, which exists naturally in the soil of certain arid and semi-arid regions. The fungus thrives in areas with hot, dry summers and mild winters, making California, Arizona, and parts of Nevada, New Mexico, and northern Mexico prime endemic zones. The disease is transmitted through inhalation of fungal spores called arthroconidia. When soil containing the fungus is disturbed by activities such as construction, farming, excavation, or strong winds, the microscopic spores become airborne and can travel significant distances. People become infected by breathing in dust particles that are contaminated with the microscopic spores. Importantly, Valley Fever is not contagious between people or animals, meaning that an infected person can't transmit the disease to another individual or pet. The infection comes exclusively from environmental exposure to contaminated soil. Weather patterns and climate change have significantly impacted the risk of transmission. Periods of increased rainfall followed by dry conditions create an ideal setting for fungal growth and subsequent dispersion of the spores. This explains why California has seen such a dramatic increase in cases following recent wet winters, as the enhanced fungal growth eventually leads to greater spore production when conditions dry out. Often Silent, Yet Potentially Deadly Fortunately, nearly 60% of those who are infected with Coccidioides will not develop symptoms. However, in the remaining 40%, symptoms typically appear one to three weeks after exposure, though they can emerge anywhere from a few days to several months later. The disease presents in various forms, ranging from mild to severe. Most people with Valley Fever experience flu-like symptoms that can persist for weeks to months. Symptoms can include persistent fatigue, fever, dry cough, chest pain, shortness of breath, headaches, muscle aches, and joint pain. Many patients also develop a characteristic skin rash with red bumps or patches. The fatigue associated with Valley Fever can be particularly debilitating and may last for months even after other symptoms resolve. In approximately 5-10% of cases, the infection may progress to a chronic pulmonary form, causing persistent pneumonia-like symptoms, with the development of lung nodules that may be seen on chest X-ray. Less commonly, the infection can spread beyond the lungs to other parts of the body, including bones, joints, skin, and the central nervous system. This disseminated form is more serious and has a higher prevalence in pregnant women, people with a compromised immune system, and certain ethnic groups including African Americans, Filipinos, and Hispanics. Testing and Diagnosis Diagnosing Valley Fever can be challenging because its symptoms may closely resemble other respiratory illnesses. Many cases go undiagnosed or are misdiagnosed, leading to unnecessary antibiotic treatment and delayed prescription of antifungal medication. Several testing methods are available for diagnosis. Blood (i.e., serology) tests can detect antibodies that the immune system produces in response to the fungal infection. The fungus can also be grown in culture, but this can take several days, which may delay diagnosis and treatment. Molecular, or PCR, tests are available at select laboratories and can provide a rapid diagnosis from samples such as sputum, tissue or cerebrospinal fluid. Healthcare providers should consider Valley Fever testing for patients in endemic areas who present with persistent respiratory symptoms, especially during peak transmission seasons, which are usually late fall and early winter. Prevention Strategies While it's impossible to completely eliminate the risk of Valley Fever in endemic areas, several measures can significantly reduce the risk of becoming infected. The most effective prevention involves minimizing exposure to dust and disturbed soil. During high-risk periods, particularly windy days or dust storms, people should stay indoors with windows and doors closed and use air purification systems with high-efficiency filters. When outdoor activities are necessary, wearing a mask can provide protection against inhaling fungal spores. Those working in high-risk occupations, such as construction or agriculture, should use appropriate respiratory protection. Individuals at higher risk for severe disease, including pregnant women or those with a compromised immune system, should take extra precautions. This may include avoiding high-risk activities entirely and consulting with their healthcare provider about steps to stay safe and symptoms to watch out for. As Valley Fever cases continue to climb in California and other southwestern states, awareness and prevention become increasingly important. Understanding this fungal disease, recognizing its symptoms, and taking appropriate protective measures can help individuals and communities better navigate this growing public health challenge.
